Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Sareum announces positive results from kinase inhibitor trial
(Sharecast News) - Sareum Holdings announced positive topline results from its phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor under development for treating autoimmune diseases. The AIM-traded firm said the trial's multiple ascending dose stage revealed that blood plasma levels of SDC-1801 exceeded predicted therapeutic exposure levels, with a half-life of 17 to 20 hours, indicating potential for once-daily dosing.
It said the safety review committee reported no deaths or serious adverse events linked to SDC-1801.
Additionally, initial data, which remained blinded, showed no significant changes in blood cell counts or serum creatinine levels, common dose-limiting side effects seen with brepocitinib, a similar TYK2/JAK1 inhibitor.
"We are delighted that the dosing of subjects in the SDC-1801 clinical trial has been completed successfully and without any serious adverse events," said chief executive officer Dr Tim Mitchell.
"We look forward to building a strong data package to advance SDC-1801 to the next stage of its development."
Sareum said further detailed, unblinded data, including mild or moderate adverse events and biomarkers of TYK2 and JAK1 inhibition, was expected in the third quarter of 2024.
"The success of this stage of the clinical trial demonstrates that high blood levels of a dual TYK2/JAK1 kinase inhibitor can be achieved without serious side effects," added chief scientific officer Dr John Reader.
"Together with the long half-life observed, we believe this potentially gives SDC-1801 significant advantages over its competitors.
"We're grateful to the volunteers who participated in this trial, and to the clinical staff who enabled its timely completion."
At 1056 BST, shares in Sareum Holdings were up 8.31% at 48.2p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.